Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ambry Genetics | RCV000215421 | SCV000276017 | uncertain significance | Hereditary cancer-predisposing syndrome | 2015-05-27 | criteria provided, single submitter | clinical testing | |
Gene |
RCV000236914 | SCV000293776 | uncertain significance | not provided | 2015-12-28 | criteria provided, single submitter | clinical testing | This variant is denoted ATM c.2569C>G at the cDNA level, p.Leu857Val (L857V) at the protein level, and results in the change of a Leucine to a Valine (CTA>GTA). This variant has not, to our knowledge, been published in the literature as pathogenic or benign. ATM Leu857Val was not observed in approximately 6,500 individuals of European and African American ancestry in the NHLBI Exome Sequencing Project, suggesting it is not a common benign variant in these populations. Since Leucine and Valine share similar properties, this is considered a conservative amino acid substitution. ATM Leu857Val occurs at a position where amino acids with properties similar to Leucine are tolerated across species and is not located in a known functional domain (Tavtigian 2009, Stracker 2013). In silico analyses are inconsistent regarding the effect this variant may have on protein structure and function. Based on currently available evidence, it is unclear whether ATM Leu857Val is a pathogenic or benign variant. We consider it to be a variant of uncertain significance. |